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Abstract
Background: Transient global forebrain ischemia causes selective, delayed death of hippocampal CA1 pyramidal neurons,
and the ovarian hormone 17b-estradiol (E2) reduces neuronal loss in young and middle-aged females. The neuroprotective
efficacy of E2 after a prolonged period of hormone deprivation is controversial, and few studies examine this issue in aged
animals given E2 treatment after induction of ischemia.
Methodology/Principal Findings: The present study investigated the neuroprotective effects of E2 administered
immediately after global ischemia in aged female rats (15–18 months) after 6 months of hormone deprivation. We also
used electrophysiological methods to assess whether CA1 synapses in the aging hippocampus remain responsive to E2 after
prolonged hormone withdrawal. Animals were ovariohysterectomized and underwent 10 min global ischemia 6 months
later. A single dose of E2 (2.25 mg) infused intraventricularly after reperfusion significantly increased cell survival, with 45%
of CA1 neurons surviving vs 15% in controls. Ischemia also induced moderate loss of CA3/CA4 pyramidal cells. Bath
application of 1 nM E2 onto brain slices derived from non-ischemic aged females after 6 months of hormone withdrawal
significantly enhanced excitatory transmission at CA1 synapses evoked by Schaffer collateral stimulation, and normal long-
term potentiation (LTP) was induced. The magnitude of LTP and of E2 enhancement of field excitatory postsynaptic
potentials was indistinguishable from that recorded in slices from young rats.
Conclusions/Significance: The data demonstrate that 1) acute post-ischemic infusion of E2 into the brain ventricles is
neuroprotective in aged rats after 6 months of hormone deprivation; and 2) E2 enhances synaptic transmission in CA1
pyramidal neurons of aged long-term hormone deprived females. These findings provide evidence that the aging
hippocampus remains responsive to E2 administered either in vivo or in vitro even after prolonged periods of hormone
withdrawal.
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Introduction
Transient global or forebrain ischemia during cardiac arrest
affects 150,000 Americans each year, most of them elderly [1], and
in many cases results in selective, delayed death of hippocampal
CA1 neurons [2] and severe cognitive deficits [3]. Although basic
research provides solid evidence that the ovarian hormone 17b-
estradiol (E2) exerts profound neuroprotective effects in young and
middle-aged female and in young male rodents [4], whether E2
retains its neuroprotective actions against ischemia-induced brain
damage in aging hippocampus after a prolonged period of
hormone withdrawal is controversial.
It has been proposed that there is limited time window for E2 to
retain its beneficial effects after loss of ovarian function due to
surgical or natural menopause. The existence of this time window
for beneficial actions of E2 was originally reported in an animal
study [5], and was then proposed to explain why large clinical
trials, such as the Women’s Health Initiative and the Women
Estrogen Stroke Trial, reported that hormone therapy (HT) did
not reduce the incidence of cardiovascular and neurodegenerative
diseases or cognitive impairment in elderly women [6,7,8]. Indeed,
these studies indicated that HT may increase the risk of stroke and
dementia in postmenopausal women who initiated treatment long
after menopause [9]. Subsequent studies of animals undergoing
focal and global ischemia provided further evidence for a limited
time window for E2 neuroprotection. One week pretreatments
that maintain low physiological E2 levels (10–25 pg/ml) protect
young mice from focal ischemia [10] and young and middle-aged
rats [11] from global ischemia-induced brain damage when
initiated immediately after ovariectomy, but not when initiated
10 weeks later. E2 pellets that maintain high physiological
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infarcts in reproductively senescent, middle-aged females [12,13].
Similarly, one week treatment with proestrous levels of E2 (64 pg/
ml) initiated at the time of ovariectomy is protective after global
ischemia in young and middle-aged rats, but not in 24 month-old
females, which are likely to have ceased normal estrous cycles for
many months [14].
Nonetheless, there is evidence that under some circumstances
E2 retains its neuroprotective action after long-term loss of ovarian
function. A single high dose of E2 (4 mg/kg) administered 30 min
before global ischemia prevents neuronal loss in 18 month-old
gerbils ovariectomized for two weeks to the same extent as in
young and middle-aged females [15]. Similarly, two-week pre-
treatment with high physiological doses of E2 in middle-aged
females ovariohysterectomized (OVX) for 0, 1 or 8 weeks
ameliorates ischemia-induced hippocampal neuron death in all
rats regardless OVX interval [16]. One week hormone re-
placement also reduces focal ischemia-induced brain damage in
reproductively senescent, middle-aged females [17,18]. Moreover,
a high dose of E2 administered either systemically or intraven-
tricularly immediately after global ischemia is neuroprotective in
middle-aged females 2 months after OVX [19]. These findings
suggest that the dose, timing and type of E2 administration may be
critical factors.
The present study addressed unanswered, yet important
questions about the efficacy of E2 treatment initiated after an
ischemic event in aged female rats subjected to long-term loss of
ovarian function. The investigation of acute post-ischemic E2
administration in old animals is of great clinical relevance as the
incidence of stroke increases with age, specifically in women after
menopause [20]. Moreover, treatment that can be administered
after the onset of ischemia is more clinically relevant than
pretreatment. Therefore, we tested the neuroprotective effects of
E2 administered immediately after global ischemia in aged female
rats after 6 months of hormone deprivation. In addition, we used
electrophysiology to assess whether CA1 synapses in the aging
hippocampus remain responsive to E2 in age-matched, non-
ischemic females 6 months after OVX.
Materials and Methods
Animals and Ethics Statement
All experiments were conducted in accordance with the
National Institutes of Health Guidelines for Care and Use of
Animals in Research and were approved by the Institutional
Animal Care and Use Committee at Albert Einstein College of
Medicine. Middle-aged (retired breeders, 9–11 months) and young
(2 months) female Sprague-Dawley rats were obtained from
Charles River (Wilmington, DE) and housed in groups of 2–3.
Retired breeders were chosen because the majority of middle-aged
women have had at least one pregnancy. Thus, retired breeders
are more clinically relevant than virgin females. All rats were
bilaterally OVX under isoflurane anesthesia (4% induction, 2%
maintenance in 70% N2O:30% O2). Young rats were used only
for slice studies and were OVX for 7–10 days before experimen-
tation.
Body Weight
Because E2 reduces food intake and long–term hormone
withdrawal increases body weight [21,22], OVX animals were
weighed every month after OVX. Body weight was also measured
before and after ischemia/sham-operation, and again when rats
were killed for histological analysis.
Global Ischemia
Rats were subjected to transient global ischemia by four vessel
occlusion or sham surgery as previously described [23]. Briefly,
rats were deeply anesthetized with isoflurane, and the vertebral
arteries were occluded bilaterally to prevent collateral blood flow
to the forebrain during the subsequent occlusion of the common
carotid arteries. One day later, transient global ischemia was
induced by bilateral occlusion of the carotid arteries for 10 min.
Pupil dilation and the loss of righting reflex were monitored every
minute during carotid occlusion to verify ischemia. Rectal
temperature was maintained at 36.5–37.5uC until recovery from
anesthesia. Sham-operated rats underwent all procedures except
carotid artery occlusion. Of the 48 rats that underwent global
ischemia or sham surgery 6 months after OVX, 13 died during or
after surgery, and 3 were excluded because they either failed to
show neurological signs of ischemia or awakened during occlusion.
Hormone Treatment
E2 was dissolved in vehicle (100% DMSO) at a dose previously
shown to reduce CA1 cell death in young and middle-aged females
[19]. E2 or vehicle was administered immediately after reperfu-
sion. A 26 ga needle was lowered into the right lateral ventricle
using standard stereotaxic procedures. Vehicle or 2.25 mgo fE 2i n
5 ml of DMSO was infused at a flow rate of 5 ml/min. For
subcutaneous injection, E2 was dissolved in 100% ethanol at
10 mg/ml, then further diluted in peanut oil. A final dose of
100 mg/kg of E2 was injected at the time of reperfusion. This dose
is neuroprotective in young and middle-aged, OVX females
[19,24].
Histological Analysis
One week after global ischemia or sham surgery, rats were
transcardially perfused with 0.9% saline followed by ice cold 10%
phosphate buffered formalin (Fisher Scientific, Pittsburgh, PA).
Brains were removed, placed in formalin at 4uC overnight, fixed in
30% sucrose in phosphate buffered saline at 4uC for 5 days and
then frozen at 280uC. Coronal sections (20 mm) were cut at the
level of the dorsal hippocampus (3.3–4.0 mm posterior from
bregma), and 4 sections (at 140 mm intervals) per animal were
mounted and stained with haematoxylin and eosin. Medial,
middle, and lateral sectors (2506250 mm each) from the CA1, and
one sector each from the CA3 and CA4 regions of the left and
right hippocampus, were photographed at 406 magnification
using an Olympus microscope and digital camera. Digital images
were opened in Adobe Photoshop, and the number of viable
pyramidal neurons in each region of interest was counted.
Surviving neurons had rounded cell bodies and clearly visible
nucleoli. Pyknotic and shrunken neurons were not counted. CA1
cell counts in each sector (medial, middle and lateral) were
summated over right and left hemispheres to calculate the total
number of surviving CA1 pyramidal neurons in all 4 sections for
each of the 3 sectors. Similarly, surviving pyramidal neurons in left
and right CA3 and CA4 were summed in each subfield. All cell
counts were carried out by an investigator who was blind to the
animals’ treatment.
Electrophysiological Recordings
OVX rats were anesthetized with isoflurane and decapitated,
and the brains were removed into chilled cutting solution
consisting of (in mM) 215 sucrose, 2.5 KCl, 20 glucose,
26 NaHCO3, 1.6 NaH2PO4, 1 CaCl2, 4 MgCl2, and 4 MgSO4.
Transverse slices (400 mm) of dorsal hippocampus were prepared
with a Leica VT1200 S (Leica, Nussloch, Germany) vibrating
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recording solution), which was gradually replaced within 1 h with
extracellular recording solution (aCSF) containing the following (in
mM): 124 NaCl, 2.5 KCl, 10 glucose, 26 NaHCO3, 1 NaH2PO4,
2.5 CaCl2, and 1.3 MgSO4. All solutions were saturated with 95%
O2 and 5% CO2, pH 7.4. Slices were incubated for at least 1 h in
the recording solution before experiments.
Experiments were conducted in a submersion-type recording
chamber (0.8 ml volume) perfused at 2 ml/min, and the
temperature was maintained at 2861uC using a TC-344B dual-
channel heater controller (Warner Instruments, Hamden, CT).
Field excitatory postsynaptic potentials (fEPSPs) were evoked in
CA1 by electrical stimulation (0.05 Hz) of the Schaffer collateral
pathway with a monopolar stimulating electrode filled with aCSF
and a glass recording electrode filled with 1 M NaCl, both
positioned in the middle third of stratum radiatum in the CA1
region. The recording and stimulating electrodes were placed at
the same depth (60–100 mm), and the distance between them was
kept constant. Recordings were performed with a MultiClamp
700A amplifier (Molecular Device, Sunnyvale, CA), and output
signals were filtered at 3 kHz. Data were digitized (5 kHz
sampling frequency) and analyzed online using a macro written
in IgorPro (Wavemetrics, Portland, OR). fEPSP slopes (mV/ms)
were recorded with stimulus intensities yielding 40–50% of the
maximum response. After at least 15 min of stable baseline
recordings in solution containing 0.01% DMSO (vehicle for E2
perfusion), 1 nM of E2 was bath applied. LTP was induced with
high frequency stimulation (2 trains of 100 stimuli at 100 Hz,
separated by 20 s) after 20 min of stable baseline recordings in the
solution containing 1 nM E2.
Statistical Analysis
Data are expressed as mean 6 SEM. Changes in body weights
over 6 months after OVX were analyzed by repeated measures
ANOVA with Newman-Keuls post-hoc comparison. Loss of body
weight after ischemia/sham operation (calculated by subtracting
body weight on day 7 after surgery from pre-ischemia body
weight) was tested by 2 way ANOVA (ischemia x hormone
treatment) followed by Newman-Keuls post-hoc tests. Cell count
data were first analyzed using two-way ANOVA (ischemia6hor-
mone treatment). If significant main effects or interactions were
found, data were further evaluated as follows. 1) Cell counts in
sham groups were tested by Mann Whitney U-test (sham vehicle
vs. sham E2). Because they did not differ, the data were combined
into a single sham group. 2) Cell counts in ischemic rats relative to
sham were tested using one-way ANOVA (sham vs. ischemia +
vehicle vs ischemia + E2) followed by Tukey HSD. For
electrophysiological data, the averaged responses for 5 min
baseline recording (last 5 min before E2 infusion or LTP
induction), and the averaged responses during 25–30 min after
the start of E2 application or complete delivery of tetanus,
respectively, were analyzed using two-way ANOVA (treatmen-
t6age) followed by post-hoc tests (paired t-tests or Mann–Whitney
U tests as appropriate). The magnitude of effect was calculated as
the percentage change between the two time periods described
above and tested by Mann–Whitney U tests. A two tailed p,0.05
was considered significant.
Results
Body Weight
Changes in body weight after OVX were monitored for
6 months to confirm physiological effects of E2 deprivation over
time. As shown in Fig. 1A, all animals gained weight after OVX
(F=148.2, p,0.0001). Average body weight was 391610 g at the
time of OVX and increased to 459610 g (16% increase),
498612 g (27% increase) and 543614 g (39% increase) at 2, 4
and 6 months after OVX, respectively. Body weights at each time
point differed significantly (p,0.001 for all time points). We also
calculated the loss of weight due to surgery by subtracting body
weight on day 7 after surgery from pre-ischemia body weight.
Animals in all groups significantly lost weight after ischemia/sham
operation (Fig. 1B). There was a significant main effect of ischemia
(F=4.38, p,0.05), with ischemic rats losing more weight than
sham-operated rats, but not of hormone treatment (F=0.14,
p,0.91), indicating that acute E2 administration did not affect
weight loss after ischemia/sham operation.
CA1 Pyramidal Cell Survival
For sham-operated animals, 2-way ANOVA followed by post-
hoc testing indicated that there was no significant hormone effect
(z=21.23, p=0.29). Therefore, the data were combined into
a single sham group for illustration in Fig. 2. Global ischemia
produced massive CA1 pyramidal cell death in all ischemic
Figure 1. Body weight increased significantly after OVX. Panel A:
The body weight of middle-aged females rats over 6 months after OVX.
Panel B: The difference in body weight measured at the time of
ischemia and 7 days later, when animals were killed for histological
evaluation. Entries are means 6 SEM. ***, p,0.001 vs. all other time
points; *, p,0.05.
doi:10.1371/journal.pone.0038018.g001
Estradiol and Ischemia in Aging Hippocampus
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38018animals relative to sham-operated rats, indicated by a significant
main effect of ischemia (F=124.5, p,.0001). There was also
a significant interaction between ischemia and hormone (F =11.9,
p,.001). Post-ischemic infusion of E2 into the ventricle signifi-
cantly increased the number of surviving CA1 neurons (F=77.5,
p,0.001) in ischemic animals (45% survival in hormone-treated
rats versus 15% in controls, p,0.003), indicating that post-
ischemic E2 administration reduces CA1 cell death in old OVX
female rats after 6 months of hormone deprivation. This level of
protection is similar to that reported in our previous study, where
the same dose of E2 rescued 52% of CA1 neurons in middle-aged
rats OVX for 2 months [19]. Therefore, we analyzed whether
CA1 survival rates are significantly different between middle-aged
females OVX for 2 (data from ref 19) or aged females OVX for 6
months (Fig. 2). Mann-Whitney U tests revealed no significant
differences (z=21.22, p=0.25), which suggests this dose of E2
rescues CA1 neurons to the same extent at both OVX intervals.
Because systemic injection of hormone is more clinically
relevant than intraventricular infusion and some studies showed
subcutaneous injection of E2 after ischemia is neuroprotective in
young and middle-aged females [19,24,25], we injected a separate
group of 6 month OVX rats (n=8 ) subcutaneously with 100 mg/
kg of E2. Only 17% of CA1 pyramidal neurons survived in these
E2-treated ischemic rats (data not shown), which was significantly
different from sham (p,0.001) and ischemic rats infused in-
traventricularly with E2 (p,0.01), but not from vehicle-treated
ischemic animals (p=0.99).
CA3 and CA4 Pyramidal Cell Survival
We observed substantial CA3 and CA4 cell loss in some sections
from 6 month OVX animals subjected to global ischemia. As
shown in Fig.3, ischemia produced moderate (about 30%
compared to sham), but significant pyramidal cell loss in vehicle-
treated ischemic animals in both CA3 (F=7.13, p,0.01) and CA4
(F=5.86, p,0.05) areas. There were no differences in cell counts
in vehicle- and E2-treated sham rats in CA3 (z=20.37, p=0.73)
or CA4 (z=20.25, p=0.91). Thus, sham data were combined
and used for post-hoc tests. Infusion of E2 tended to reduce
neuronal loss to about 10–15%, but the effect of E2 was not
statistically significant (Fig. 3B). To determine whether CA3/CA4
cells are vulnerable to ischemia in middle-aged females subjected
to shorter periods of hormone deprivation, we counted CA3 and
CA4 pyramidal cells from middle-aged, retired breeders subjected
to ischemia or sham surgery 2 months after OVX and treated
intraventricularly with vehicle or E2 as described in Methods.
Ischemia did not affect CA4 cell counts (F=2.18, p,0.15), but
significantly reduced CA3 pyramidal neurons (about 12% cell loss,
F=6.13, p,0.05) in these animals (Fig. 3C). There was a tendency
for E2 to attenuate CA3 pyramidal cell death in ischemic rats, but
the effect was not significant.
Synaptic Physiology
We recorded fEPSPs at CA3-CA1 synapses elicited by
Schaffer collateral stimulation in acute hippocampal slices
prepared from aged (15–18 mo, 6 months after OVX) and
young adult (2 mo, 7–10 days after OVX) females. Bath
application of E2 (1 nM) significantly enhanced synaptic
responses (F=43.1, p,0.001, Fig.4) in slices from both young
(110.261.0% of baseline, 7 slices from 6 animals, p,0.01 vs.
baseline) and aged (109.162.4% of baseline, 5 slices from 4
animals, p,0.01 vs. baseline) OVX rats with a similar latency
(approximately 5–7 min) and magnitude measured 25–30 min
after the start of E2 application.
Because we had very few old animals for electrophysiological
studies, the LTP experiments were carried out in slices exposed
to E2, after they had achieved a stable fEPSP. In slices from
young females recorded under our conditions, 1 nM E2 does not
modify LTP induced by high frequency stimulation (data not
shown). fEPSPs were significantly potentiated after high frequen-
cy stimulation (F=21.8, p,0.01, Fig.5) in slices from young
(129.966.1% of baseline, 7 slices from 6 animals, p,0.001 vs.
baseline) and aged (116.262.1% of baseline, 4 slices from 4
animals, p,0.05 vs. baseline) OVX rats. The magnitude of LTP
Figure 2. E2 given intraventricularly affords neuroprotection in
aged female rats 6 months after OVX. Aged female rats were
subjected to sham surgery or global ischemia 6 months after OVX.
Panel A: Surviving CA1 pyramidal neurons were counted bilaterally in 3
sectors (250 mm6250 mm each) of 4 sections of the dorsal hippocam-
pus (top left). Representative photomicrographs of neurons in dorsal
CA1 one week after sham or ischemia (Isch) surgery in rats infused
immediately with vehicle (veh) or 2.25 mg of E2. Scale bars, 60 mm. SO,
stratum oriens; SP, stratum pyramidale; SR, stratum radiatum. Panel B:
Surviving pyramidal neurons in the CA1 subfield of the hippocampus
were quantified 7 days after ischemia. Because there were no significant
differences in cell counts in vehicle (black circles) and E2 (gray circles)
treated sham rats, data were combined and shown as a single sham
group. Data are means 6 SEM and represent the grand sum of neurons
in all 3 counting sectors from all 4 sections. ***, p,0.001 versus
ischemia; **, p,0.01 versus ischemia/vehicle.
doi:10.1371/journal.pone.0038018.g002
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surgery or global ischemia 2 or 6 months after OVX. Because there were no significant differences in cell counts in vehicle (black circles) and E2 (gray
circles) treated sham rats, data were combined and shown as a single sham group. Panel A: Surviving CA3 and CA4 pyramidal neurons
(250 mm6250 mm) were counted bilaterally in one sector of 4 sections of the dorsal hippocampus (top panel). Representative photomicrographs of
neurons in the CA3 and CA4 subfield in sham (middle panel) and ischemia+vehicle (bottom panel) groups. Panel B: Surviving CA3 (left) and CA4
(right) neurons in females OVX for 6 months and assessed at 1 week after sham or ischemia surgery and treated intraventricularly with vehicle or
2.25 mg of E2. Panel C: Surviving CA3 (left) and CA4 (right) neurons in females OVX for 2 months and assessed 1 week after sham or ischemia surgery
and treated intraventricularly with vehicle or 2.25 mg of E2. Data are means 6 SEM. *, p,0.05 versus sham.
doi:10.1371/journal.pone.0038018.g003
Figure 4. CA1 synapses in the aging hippocampus retain responsiveness to E2 after long-term hormone deprivation. Evoked fEPSPs
were measured in acute hippocampal slices from aged (15–18 mo, 6 months after OVX) and young (2 mo, 7–10 days after OVX) females. E2 (1 nM)
was bath applied after 15 min stable baseline. Panel A: E2 facilitated fEPSPs in young (open circles) and aged (black circles) females with short latency.
Panel B: Representative fEPSPs from young (n=7 slices from 6 rats) and aged (n=5 slices from 4 rats) rats before and after E2 application. Panel C: The
averaged responses for the last 5 min baseline recording and the averaged responses during 25–30 min after the start of E2 application. Data are
means 6 SEM. n.s., not significant. **, p,0.01.
doi:10.1371/journal.pone.0038018.g004
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young OVX animals.
Discussion
The current study addressed the efficacy of E2 to protect CA1
pyramidal neurons in old, long-term hormone deprived female
brain in a clinically relevant model of global ischemia, examining
whether a high dose of E2 administered immediately after
ischemia is neuroprotective in aging hippocampus. Here, we
report that a single dose of E2 infused intraventricularly
immediately after ischemia ameliorates CA1 pyramidal neuron
death in 15–18 month female rats after 6 months of hormone
withdrawal. We also show that bath application of E2 facilitates
fEPSPs at CA1 synapses and that high frequency stimulation
induces LTP in acute slices from aged females OVX for 6 months
to the same extent as in young adult females. These results provide
strong evidence that the aging female hippocampus retains
responsiveness to the neuroprotective actions of high doses of E2
even after prolonged periods of hypoestrogenicity.
E2 is Neuroprotective in Aged, Long-term Hormone-
deprived Female Rats
The finding that E2 retains its ability to protect the aging
hippocampus from ischemic injury is consistent with our previous
report that post-ischemic infusion of E2 and some estrogen analogs
that do not bind classical estrogen receptors (ERs), such as the
GPR30 agonist G1 [26] and the membrane-associated ER agonist
STX [27,28], attenuate ischemia-induced cell death in middle-
aged females OVX for 2 months before experimentation [19].
Thus, our data provide additional evidence that post-ischemic
infusion of E2 is neuroprotective in old rats even after extended
periods of hypoestrogenicity. In contrast, systemic injection of E2
(100 mg/kg) in a dose that rescued CA1 neurons in middle-aged
rats OVX for 2 months [19] was not effective in rats that were
OVX for 6 months. The different outcomes between intraven-
tricular and systemic E2 treatment may relate to the dramatically
increased body weights observed in 6 month OVX females. As
shown in Fig. 1, weights in rats OVX for 6 months increased by
almost 40%, and most of the weight gain is due to increased
adiposity. Thus, one possible explanation is that increased body fat
reduces or slows the ability of subcutaneously injected E2, which is
highly lipophilic, to reach the target brain areas in high
concentrations. Supporting this idea, when E2 is directly
administered into the brain ventricles, CA1 pyramidal cell survival
rates in ischemic females OVX for 6 and 2 months (45% and 52%
survival, respectively) are not statistically different. Because obesity
worsens apoptosis and neuroinflammation after hypoxic ischemia
[29], this may also contribute to the reduced efficacy of
systemically administered E2.
In contrast with our results, several investigators report that E2
loses its ability to protect neurons from focal and global ischemia if
hormone treatment is not initiated shortly after OVX
[10,11,12,13,14], even in young animals. Several possible ex-
planations may account for the different findings. First, three of
the studies examined outcomes after focal ischemia [10,12,13]
induced by middle cerebral artery occlusion (MCAO), whereas we
induced transient global ischemia. The focal and global ischemia
models differ in several ways, including the nature of brain injury
and the specific brain regions involved. Thus, sensitivity to
exogenous E2 treatment after prolonged OVX intervals may
depend on the type of brain damage and the affected brain region.
Yet the most likely explanation for the differing outcomes
between our work and others may be the dose and timing of E2
administration [30]. Studies that found no beneficial effects of E2
after long-term loss of ovarian hormones administered E2
chronically for days or weeks prior to ischemia using methods
that maintain physiological levels of E2 (10–80 pg/ml)
[10,11,12,13,14]. These studies attempt to mimic circulating
hormone levels to test the critical period hypothesis in a model
similar to the continuous, long-term HT used in menopausal
women. This form of neuroprotection is mediated through slow
Figure 5. Aged hippocampus exhibits normal LTP. Acute hippocampal slices were prepared from aged (15–18 mo, 6 months after OVX) and
young (2 mo, 7–10 days after OVX) females. Panel A: High frequency stimulation (HFS, 2 trains of 100 stimuli at 100 Hz) was applied after 20 min
baseline in the presence of E2. LTP was induced in slices from both young (open circles) and aged (black circles) rats. Panel B: Representative fEPSP
traces from young (n=7 slices from 6 rats) and aged (n=4 slices from 4 rats) rats before and after HFS. Panel C: Averaged responses for the last 5 min
baseline recording and the averaged responses during 25–30 min after complete delivery of tetanus. The magnitude of LTP between the two groups
was not significantly different. Data are means 6 SEM. n.s., not significant. *, p,0.05, ***, p,0.001.
doi:10.1371/journal.pone.0038018.g005
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and anti-apoptotic genes [32,33], and classical ERs play a key
role. For example, MCAO studies in mice with targeted deletion
of classical ERs [34] and in rats treated with an ER antagonist
[11,35] or selective agonists in global [36] and focal ischemia
[37] show that classical ERs, in particular ER-a, are necessary to
protect neurons against ischemia-induced brain injury. Indeed,
a recent study reports degradation of ER-a as a key mechanism
for the loss of E2 neuroprotection when global ischemia is
induced in very old rats or in younger rats subjected to long
periods of hormone deprivation, suggesting that the loss of E2
neuroprotection is associated with the degradation of hippocam-
pal ER-a in aged and long-term hormone withdrawn female rats
[14].
In contrast, the present and earlier studies that report beneficial
effects of E2 used a high dose of hormone given immediately after
[19] or 30 min before [15] ischemia. These studies test the efficacy
of E2 as a neuroprotective strategy after long-term loss of ovarian
hormones using a supraphysiological dose of E2 administered just
before or after the ischemic event. This form of E2 action may be
mediated via rapid, non-genomic, membrane-initiated E2 signal-
ing pathways [27,38,39]. For example, estrogenic compounds that
have no/little affinity for classical ERs [19,40] including several
non-feminizing estrogen analogs [41], are neuroprotective in focal
and global ischemia. These findings suggest that neuroprotective
actions of post-ischemic E2 may involve membrane-associated
estrogen binding sites that are independent of ER-a and ER-b and
that engage signaling pathways associated with cell membrane
receptors. For instance, global ischemia transiently increases Akt
phosphorylation and decreases the phosphorylation of the Akt
targets, GSK3b and FOXO3A, and activates caspase-3 in the
CA1 subfield shortly (1–3 h) after ischemia; acute post-ischemic
E2 rapidly inhibits these early events and provides histological
protection in young OVX females [42]. These findings suggest
that regulation of Akt signaling in temporal proximity to an
ischemic event is important for neuronal survival. There is also
evidence that E2 significantly increases phospho-Akt-immunore-
activity in CA1 dendritic spines of young and aged female rats
[43]. Thus, we speculate that enhanced Akt signaling may be one
possible mechanism underlying the observed neuroprotective
effects of E2, and that E2 can regulate these signaling cascades
in the aging hippocampus even after a long period of hormone
deprivation.
Accumulating evidence also indicates that acute, high-dose
treatment with E2 after ischemia effectively reduces neuronal
damage in permanent and transient focal ischemia in adult OVX
animals [25,44,45], even when treatment is delayed up to 6 h after
the onset of ischemia [24]. If delayed treatment is also effective in
old animals subjected to global ischemia, post-ischemic E2 therapy
may have great neuroprotective potential for treatment of
ischemia/stroke in post-menopausal women. Intriguingly, the
range of effective E2 concentrations in promoting neuronal
survival after ischemic insults is very large, from physiological
(100 pM) to pharmacological (50 mM) in vitro, and from 100 mg/kg
to 1000 mg/kg in vivo, depending on the timing of treatment after
ischemia [44]. The E2 dose used in the current study (2.25 mgo r
450 mg/kg) is supraphysiological, but falls into this effective
concentration range. Interestingly, concentrations of E2 in the
brain, including the hippocampus, are reported to be much higher
than circulating E2 [46,47]. Locally synthesized E2 acts in
a paracrine and autocrine manner [48], rapidly modulating
synaptic physiology and plasticity through non-genomic actions
[49,50]. Because critical enzymes required for E2 synthesis, such
as aromatase and StAR, are synaptically localized in hippocampal
neurons and glial cells [51], the possibility arises that long-term
OVX rats may retain the ability to produce some brain-derived E2
even after loss of circulating E2, and that E2 administered after
ischemia may interact with locally synthesized E2 to protect
neurons. This speculation is supported by findings indicating that
brain-derived E2 plays a role in neuroprotection [52,53,54]. In
some models, aromatase activity increases after ischemia [55,56],
and the extent of ischemic damage is greater in aromatase
knockout than in wild-type females [57]. Furthermore, MCAO
increases brain E2 concentrations, and co-injection of an
aromatase inhibitor decreases brain E2 levels and is associated
with more damage [58]. Thus, brain-derived E2 may act as
a natural neuroprotective agent. However, it is obvious that
hippocampal E2 alone is not sufficient to prevent brain damage
induced by ischemia as all studies report significant cell death after
ischemia in vehicle-treated animals.
The Aging Hippocampus is Sensitive to E2 and can
Exhibit LTP at CA1 Synapses after Long-term Hormone
Deprivation
It is well known that E2 rapidly increases excitability and basal
synaptic transmission at CA1 synapses, and under some circum-
stances enhances LTP, via non-genomic actions [59]. Although
aging affects synaptic physiology [60] and the aged hippocampus
may respond differently to E2 [61], in agreement with the
histological outcomes, the current electrophysiological experi-
ments demonstrate that application of E2 onto brain slices derived
from old females OVX for 6 months facilitates fEPSPs at CA1
synapses. This action of E2 is indistinguishable in latency and
magnitude to that recorded in slices from young rats. Moreover,
slices from old, hormone-withdrawn females exhibit normal LTP
in response to high frequency stimulation. Thus, the current results
provide solid evidence that the aging hippocampus retains some
responsiveness to E2 for at least at 6 months after OVX.
Two studies that examined the effects of long-term hormone
deprivation on E2 enhancement of CA1 synaptic transmission and
plasticity in aging hippocampus are consistent with the current
results. The first showed that E2 treatment for 2 days in vivo
increases the magnitude of LTP evoked at CA3-CA1 synapses by
high frequency stimulation, spine density and synaptic currents up
to 15 months after OVX [62]. The second reported that bath
application of E2 enhances fEPSPs by 20%, and that stable LTP is
induced by theta-burst stimulation of the Schaffer collateral
pathway in hippocampal slices from 15–16 month female rats
6 months after OVX [63]. Interestingly, the latter investigators
also found that OVX depresses actin signaling cascades involved
in synaptic plasticity, and that acute infusion of E2 rapidly
activates this pathway [64]. These findings suggest a possible
mechanism underlying short latency E2 effects at CA1 synapses
and provide evidence that the aging hippocampus retains the
ability to activate actin signaling cascades in response to E2 after
long-term loss of ovarian hormones.
The E2 concentration (1 nM) used in the electrophysiological
experiments is higher than peak circulating E2 levels (40–80 pg/
ml, approximately 109 pM) seen during proestrus in rats [59], but
it is similar to hippocampus-derived E2 levels measured in intact
females (0.5–1.7 nM) [47]. Previous studies in slices from young
rodents show dose-dependent E2 enhancement of excitatory
synaptic transmission at CA1 synapses both in males [63] and
E2-primed, OVX females [65]. In males, infusion of E2 at
concentrations of 0.01–1 nM produces a rapid, dose-dependent
and reversible increase in excitatory synaptic transmission at CA3-
CA1 synapses, and the effects 0.1–1 nM E2 are significantly
different from those observed in 0.01 nM E2 [63]. Thus, the
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between 0.01 and 0.1 nM. Similarly, in E2-primed OVX females,
bath application of 0.1 to 100 nM E2 dose-dependently
potentiates excitatory postsynaptic currents within a few minutes
[65]. Although we only tested 1 nM in this study, the comparable
effects of E2 on enhancement of fEPSP slope in slices from young
and old OVX rats suggest that a concentration-dependent E2
modulation would be observed at CA1 synapses in slices derived
from old, long-term OVX females.
Ischemia Kills Pyramidal Neurons Beyond the CA1
Subfield in Aged Rats
Another important outcome in the present study is that global
ischemia causes death of pyramidal neurons in the CA3 and CA4
subfields in older females OVX for either 2 or 6 months. It is well
documented that different populations of hippocampal neurons
have distinct vulnerability to ischemia [66,67], and that cell loss in
CA3/CA4 does not usually occur in young rodents unless the
duration of ischemia is prolonged [68]. On the other hand, age-
related changes in vulnerability of CA3 pyramidal neurons to
ischemia [69] have been reported. There is other evidence of age-
associated increases in susceptibility to brain damage [70,71,72],
and the aging hippocampus undergoes a variety of biochemical,
structural and functional changes, including reduction of IGF-1
levels [73], decreases in dendritic spines [74] and altered ER-
a distribution [61].
In a previous study, degeneration of CA3/CA4 neurons after
global ischemia was observed in young female rats OVX for 10
weeks, and pretreatment with physiological levels of E2 for one
week prior to ischemia did not rescue this cell loss [11]. In the
present experiment, it is uncertain whether acute E2 protects CA3
and CA4 neurons from ischemia-induced cell death. Cell counts
were statistically indistinguishable in sham-operated and ischemic
rats treated with E2, suggesting that there might be some
protection. However, the absence of a significant difference
between vehicle- and E2-treated ischemic rats calls this into
question. Because this pattern is the same at both OVX intervals,
perhaps there is a weak protective effect that is not influenced by
age or OVX duration.
Conclusion
In conclusion, present data show that acute post-ischemic E2
infusion into the brain ventricle ameliorates ischemia-induced
death of hippocampal CA1 pyramidal neurons in aged rats after
6 months of ovarian hormone withdrawal. Moreover, bath
application of E2 rapidly facilitates fEPSPs at CA1 synapses in
hippocampal slices from aged females OVX for 6 months with the
same short latency and magnitude observed in young females.
These results provide clear evidence that the aging female
hippocampus retains responsiveness to certain actions of E2 even
after a prolonged period of ovarian hormone deprivation. Our
data further indicate that the type of ischemia as well as the dose
and timing of E2 administration are important factors that
determine E2 responsiveness in the aging brain. These findings
have clinically important implications for potential treatment of
global ischemia in post-menopausal women.
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